【発明の名称】VLA-4インヒビター化合物

Title:

【発明の名称】VLA-4インヒビター化合物

Document Type and Number:

Japanese Patent JP2003503350

Kind Code:

A

Abstract:

Compounds that selectively inhibit the binding of ligands to alpha 4 beta 1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by formula (I). As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.

More Like This:

JP2004515526	Loxoprofen-containing intramuscular injection pharmaceutical composition
JP3827530	Substituted aryl derivatives and substituted heteroaryl derivatives, their preparation and their use as drugs
WO/2023/225334	THERAPIES WITH PPAR AGONISTS AND FGFR4 INHIBITORS

Inventors:

Baldwin, John, Jay
Edward McDonald
Moriarty, Kevin, Joseph
Sarco, Christopher, Ronald
Nobuo Machinaga
Nakayama Atsushi
Atsushi Chiba
Shin Iimura
Yoneda

Application Number:

JP2001505915A

Publication Date:

January 28, 2003

Filing Date:

June 30, 2000

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Daiichi Pharmaceutical Co., Ltd.
Pharmacopaia ink

International Classes:

A61K31/192; A61K31/40; A61K31/404; A61K31/407; A61K31/41; A61K31/426; A61K31/4439; A61K31/454; A61K31/4709; A61K31/496; A61K31/5375; A61P3/10; A61P11/06; A61P17/06; A61P19/02; A61P25/00; A61P29/00; A61P35/00; A61P37/06; A61P43/00; C07C275/42; C07C279/18; C07C335/22; C07D207/08; C07D207/09; C07D207/10; C07D207/12; C07D207/14; C07D207/16; C07D207/22; C07D207/24; C07D209/12; C07D211/26; C07D211/34; C07D211/38; C07D213/55; C07D217/02; C07D265/30; C07D277/04; C07D277/28; C07D277/48; C07D295/13; C07D295/185; C07D307/33; C07D311/20; C07D401/06; C07D401/12; C07D401/14; C07D403/12; C07D413/06; C07D491/04; C07D491/056; (IPC1-7): C07C275/42; A61K31/192; A61K31/40; A61K31/404; A61K31/407; A61K31/41; A61K31/426; A61K31/4439; A61K31/454; A61K31/4709; A61K31/496; A61K31/5375; A61P3/10; A61P11/06; A61P17/06; A61P19/02; A61P25/00; A61P29/00; A61P35/00; A61P37/06; A61P43/00; C07C279/18; C07C335/22; C07D207/08; C07D207/10; C07D207/12; C07D209/12; C07D265/30; C07D277/04; C07D401/06; C07D401/12; C07D403/12; C07D491/056

Domestic Patent References:

JP2002429344A

Foreign References:

WO1999054321A1

1999-10-28

Attorney, Agent or Firm:

Shohei Oguri (4 outside)

Previous Patent: シブトラミンおよびオルリステートを含有する医薬品組成物

Next Patent: ＳＲＣキナーゼ阻害化合物